Találati lista | Tudóstér

001-es BibID:	BIBFORM114387
035-os BibID:	(Scopus)85169934513
Első szerző:	Caporali, Roberto
Cím:	Start RA Treatment - Biologics or JAK-Inhibitors? / Roberto Caporali, Sabino Germinario, Dorottya Kacsándi, Ernest Choy, Zoltán Szekanecz
Dátum:	2024
ISSN:	1568-9972
Megjegyzések:	Janus Kinase inhibitors (JAKi) have been approved for the treatment of Rheumatoid Arthritis (RA) for several years. They are the first oral advanced treatment with efficacy similar to, if not greater than, biologic agents. Recently, concerns over their safety was raised by the results from Oral Surveillance trial suggesting that tofacitinib, one of the JAKi, was associated with higher cardiovascular adverse events and malignancies than TNF inhibitors (TNFi). Since then, regulatory authorities have added warnings to the labels of JAKi. On this purpose, whether rheumatologists should use JAKi as first line advance treatment has become a controversial topic. Some rheumatologists have argued that biologics should be first line advance treatment since there are extensive effectiveness and safety data. In addition, with the advent of biosimilar drugs, they are the most cost-effective treatment. On the other hand, JAKi are very efficacious and are generally safe apart from older and high-risk patients. When TNFi are contraindicated and in certain RA patients, especially when an oral drug is preferable, JAKi have significant advantage providing patients are involved in the decision-making process.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Autoimmunity Reviews. - 23 : 1 (2024), p.1-4. _
További szerzők:	Germinario, Sabino Kacsándi Dorottya Choy, Ernest Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat http://dx.doi.org/10.1016/j.autrev.2023.103429
Borító:
Saját polcon:

001-es BibID:	BIBFORM081581
Első szerző:	Sarzi-Puttini, Piercarlo
Cím:	Biosimilars vs originators : are they the same? / Sarzi-Puttini Piercarlo, Marotto Daniela, Caporali Roberto, Galeazzi Mauro, Atzeni Fabiola, Hamar Attila, Soós Boglárka, Szekanecz Zoltán
Dátum:	2019
ISSN:	1568-9972
Megjegyzések:	Biological drugs have revolutionised the treatment of rheumatic diseases, and the recent expiry of the patents for many biological agents has generated considerable interest among pharmaceutical companies and regulatory agencies, and led to the marketing of highly similar, low-cost versions known as biosimilars. The increasing trend of switching patients from effective but expensive drugs to their biosimilar counterparts will have a considerable economic impact in the coming years. However, although this will greatly extend patient access the latest treatments, clinicians, scientific societies and the patients themselves have expressed a number of concerns about their long-term efficacy and safety, as well as the consequences of potentially multiple switches being dictated by economic pressure rather than medical needs. Thee aim of this review is to evaluate the pros and cons of choosing biosimilars, and whether and when they can really be considered clinically equivalent to the original drugs.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Biosimilars Originators Extrapolation Interchangeability Switching
Megjelenés:	Autoimmunity Reviews. - 18 : 12 (2019), p. 1-5. -
További szerzők:	Marotto, Daniela Caporali, Roberto Galeazzi, Mauro Atzeni, Fabiola Hamar Attila Béla (1990-) (általános orvos) Soós Boglárka (1988-) (általános orvos) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: